A trio of firms have advised on a $7.2bn (£4.8bn) deal that will see German pharma giant Merck acquire lab filter and purifier manufacturer Millipore, reports The Am Law Daily.

Skadden took the lead role for Merck, fielding a team including M&A partners Peter Atkins, Hilary Foulkes and Margaret Brown, tax partner Sally Thurston, antitrust partners Frederic Depoortere, Benjamin Crisman and John Lyons, and intellectual property and technology partner Rita Rodin Johnston.

Skadden has handled several notable deals for Merck, including the sale of the company's worldwide generic drug business to Mylan Laboratories for $6.6bn (£4.4bn) in 2007.

Millipore specialises in membrane separation technology, and the company's success in manufacturing filters and purifiers for biotechnology labs and pharmaceutical firms have made it an attractive target in the M&A market.

Millipore turned to Cravath Swaine & Moore and Ropes & Gray for advice, with Cravath managing partner Robert Townsend leading the firm's team on the deal.

Cravath corporate partner George Zobitz, who has handled several high-profile pharma deals for the firm, also advised Millipore along with executive compensation and employee benefits partner Jennifer Conway and tax partner Michael Schler.

David Walek, co-chair of the technology company group at Ropes & Gray, advised Millipore along with corporate partner Craig Marcus, the head of the firm's executive compensation group. Ropes has advised Millipore since the company's founding in 1954.

The deal is expected to close in the second half of the year.

The Am Law Daily is the website of The American Lawyer, Legal Week's US sister title.